CTRI/2024/05/068176尚未招募不适用
Immunohistochemical expression of CK19 and CD56 in thyroid neoplasms
Tanu Priya1 个研究点 分布在 1 个国家目标入组 53 人开始时间: 2024年6月30日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 53
- 试验地点
- 1
- 主要终点
- CD56 and CK19
研究概览
简要总结
Title of my study is immunohistochemical expression of CK19 and CD56 in thyroid neoplasms whose objectives are to classify thyroid neoplasms on the basis of histomorphological features, to estimate the expression of IHC marker CK19 in thyroid neoplasms, to estimate the expression of IHC marker CD56 in thyroid neoplasms, to correlate the expression of CK19 and CD56 in thyroid neoplasms. Sample size is 53. All proven cases of thyroid neoplasms are included.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 10.00 Year(s) 至 80.00 Year(s)（—）
- 性别
- All
入选标准
- •All proven cases of thyroid neoplasm.
排除标准
- •non neoplastic lesions of thyroid blocks could not be retrieved cases who had undergone chemotherapy and radiotherapy.
结局指标
主要结局
CD56 and CK19
时间窗: baseline
次要结局
未报告次要终点
研究者
Tanu Priya
BPS Govt Medical College for women Khanpur Kalan Sonipat
研究点 (1)
Loading locations...
相似试验
招募中
早期 1 期
Allogeneic Anti-CD19/BCMA CAR-T for Refractory Graves' DiseaseNCT07261345Shanghai Zhongshan Hospital4
尚未招募
不适用
levels of Cell free DNA in malignant thyroid nodulesCTRI/2025/12/098345Dr Smita Sonoli200
招募中
2 期
Testing the Effectiveness of Kanchnar Guggulu and Yoga in treating Subclinical HypothyroidismCTRI/2025/02/080040Institute For Ayurved Studies Research Shri Krishna Ayush University Kurukshetra Haryana60
招募中
不适用
CompArative Analysis Between, Thymic, pulmonaRy and Pancreatic Well Differentiated High Grade Neuroendocrine TumorsNCT07429851European Institute of Oncology34
尚未招募
3 期
Adjuvant Treatment with High dose versus Low dose of RadioActive Iodine in Intermediate Risk Differentiated Carcinoma of Thyroid with Lymph Node Metastasis - RANDOMIZED OPEN LABEL PHASE 3 NON-INFERIORITY TRIALCTRI/2024/08/072715Tata Memorial Centre580